A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a ...

By 2032, the market is estimated to surpass US$ 225.53 million, with a CAGR of 2.88% from 2024 to 2032. As more treatment options become available, patients suffering from pruritus will have access to ...

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

In this video, Raj Chovatiya, MD, PhD, discussed continued updates in the use of topical ruxolitinib in pediatric patients with atopic dermatitis.

Exploring the different stages in the development of a digital measure and the activities and steps key to achieving meaningful impact for patients.

In a recent Fox News interview, Kennedy said "there's a lot of studies out there that show that if you actually do get the wild infection, you're protected later. It boosts your immune system later in ...